Application
Fig1: Western blot analysis of XRN2 on human XRN2 recombinant protein using anti-XRN2 antibody at 1/1,000 dilution.Application
Fig2: Western blot analysis of XRN2 on HEK293 (1) and XRN2-hIgGFc transfected HEK293 (2) cell lysate using anti-XRN2 antibody at 1/1,000 dilution.Application
Fig3: Western blot analysis of XRN2 on different cell lysate using anti-XRN2 antibody at 1/1,000 dilution. Positive control： Lane1: ?Raw264.7 Lane2: HEK293 Lane3: NTERA-2 Lane4: LNcap Lane5: HepG2 Lane6: HEK293 Lane7: Hela?Application
Fig4:Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-XRN2 antibody. Counter stained with hematoxylin.Application
Fig5: Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissue using anti- XRN2 antibody. Counter stained with hematoxylin.| Product Name | XRN2 |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | 5' 3' exoribonuclease 2 antibody DHM1 like protein antibody DHP protein antibody XRN 2 antibody |
| Product description | Degradation of mRNA is a critical aspect of gene expression that occurs via the exoribonuclease. Exoribonuclease 2 (XRN2) is the human homologue of the Saccharomyces cerevisiae RAT1, which functions as a nuclear 5' to 3' exoribonuclease and is essential for mRNA turnover and cell viability. XRN2 also processes rRNAs and small nucleolar RNAs (snoRNAs) in the nucleus. XRN2 moves along with RNA polymerase II and gains access to the nascent RNA transcript after the endonucleolytic cleavage at the poly(A) site or at a second cotranscriptional cleavage site (CoTC). CoTC is an autocatalytic RNA structure that undergoes rapid self-cleavage and acts as a precursor to termination by presenting a free RNA 5' end to be recognized by XRN2. XRN2 then travels in a 5'-3' direction like a guided torpedo and facilitates the dissociation of the RNA polymerase elongation complex. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBIHC |
| WB:1:500-1:2,000 IHC:1:200-1:500 |
|
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | 5' 3' exoribonuclease 2 antibody DHM1 like protein antibody DHP protein antibody XRN 2 antibody |
|---|---|
| Molecular Weight(MW) | 109 kDa |
| Cellular Localization | Nucleus. Nucleolus. |
| SwissProt ID | Q9H0D6 |
|---|
Application
Fig1: Western blot analysis of XRN2 on human XRN2 recombinant protein using anti-XRN2 antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of XRN2 on HEK293 (1) and XRN2-hIgGFc transfected HEK293 (2) cell lysate using anti-XRN2 antibody at 1/1,000 dilution.
Application
Fig3: Western blot analysis of XRN2 on different cell lysate using anti-XRN2 antibody at 1/1,000 dilution. Positive control： Lane1: ?Raw264.7 Lane2: HEK293 Lane3: NTERA-2 Lane4: LNcap Lane5: HepG2 Lane6: HEK293 Lane7: Hela?
Application
Fig4:Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-XRN2 antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissue using anti- XRN2 antibody. Counter stained with hematoxylin.| Positive Control | Human XRN2 recombinant protein, XRN2-hIgGFc transfected HEK293 cell lysate, Raw264.7, HEK293, NTERA-2, LNcap, HepG2, Hela, human colon cancer tissue, human ovarian cancer tissue. |
|---|---|
| Application Notes | WB:1:500-1:2,000 IHC:1:200-1:500 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
